JP2020534246A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534246A5
JP2020534246A5 JP2019571517A JP2019571517A JP2020534246A5 JP 2020534246 A5 JP2020534246 A5 JP 2020534246A5 JP 2019571517 A JP2019571517 A JP 2019571517A JP 2019571517 A JP2019571517 A JP 2019571517A JP 2020534246 A5 JP2020534246 A5 JP 2020534246A5
Authority
JP
Japan
Prior art keywords
patent document
domperidone
dopamine
receptors
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534246A (ja
JP7602324B2 (ja
Filing date
Publication date
Priority claimed from US15/639,431 external-priority patent/US10266516B2/en
Application filed filed Critical
Publication of JP2020534246A publication Critical patent/JP2020534246A/ja
Publication of JP2020534246A5 publication Critical patent/JP2020534246A5/ja
Priority to JP2022205876A priority Critical patent/JP2023052045A/ja
Application granted granted Critical
Publication of JP7602324B2 publication Critical patent/JP7602324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571517A 2016-02-04 2018-06-28 重水素化ドンペリドン組成物、方法、及び調製 Active JP7602324B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205876A JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
US15/639,431 US10266516B2 (en) 2016-02-04 2017-06-30 Deuterated domperidone compositions, methods, and preparation
US15/639,431 2017-06-30
PCT/US2018/039928 WO2019006078A1 (en) 2016-02-04 2018-06-28 DETERERATED DOMPERIDONE COMPOSITIONS, METHODS AND PREPARATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205876A Division JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Publications (3)

Publication Number Publication Date
JP2020534246A JP2020534246A (ja) 2020-11-26
JP2020534246A5 true JP2020534246A5 (https=) 2021-08-19
JP7602324B2 JP7602324B2 (ja) 2024-12-18

Family

ID=59501077

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535888A Active JP7296185B2 (ja) 2016-02-04 2017-02-03 重水素化ドンペリドン組成物及び疾患の治療方法
JP2019571517A Active JP7602324B2 (ja) 2016-02-04 2018-06-28 重水素化ドンペリドン組成物、方法、及び調製
JP2022205876A Pending JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018535888A Active JP7296185B2 (ja) 2016-02-04 2017-02-03 重水素化ドンペリドン組成物及び疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205876A Pending JP2023052045A (ja) 2016-02-04 2022-12-22 重水素化ドンペリドン組成物、方法、及び調製

Country Status (11)

Country Link
US (2) US10266516B2 (https=)
EP (2) EP3411031B1 (https=)
JP (3) JP7296185B2 (https=)
KR (2) KR102851614B1 (https=)
CN (4) CN108697700B (https=)
AU (2) AU2017213852B2 (https=)
BR (2) BR112018016032B1 (https=)
CA (1) CA3055777A1 (https=)
DK (2) DK3411031T3 (https=)
EA (2) EA035515B1 (https=)
WO (2) WO2017136617A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017136617A1 (en) * 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
BR112020025208A2 (pt) * 2018-06-21 2021-03-09 Dermavant Sciences GmbH Formulações tópicas de inibidores de dgat1 e seus métodos de uso
KR20240068762A (ko) 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
WO2020086950A1 (en) * 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing domperidone
WO2022212246A1 (en) * 2021-03-29 2022-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-enzyme nanoparticle-assisted stable isotope incorporation into small molecules by channeling
EP4525868A1 (en) * 2022-04-20 2025-03-26 CinDome Pharma, Inc. Deuterated domperidone for treating gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
TW466119B (en) * 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
DK1545475T3 (da) 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
EP1830824B1 (en) 2004-12-31 2016-01-13 Iceutica Pty Ltd. Nanoparticle composition and methods for synthesis thereof
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
CN100435795C (zh) * 2006-02-27 2008-11-26 南京长澳医药科技有限公司 一种微粉化马来酸多潘立酮药物组合物及其制备方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
NZ705763A (en) 2006-06-30 2016-10-28 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AU2008245580A1 (en) 2007-04-26 2008-11-06 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone
CA2696063C (en) 2007-08-15 2014-05-06 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing form
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US20110160253A1 (en) 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010054003A2 (en) * 2008-11-06 2010-05-14 Auspex Pharmaceutical, Inc. Methylindazole modulators of 5-ht3 receptors
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
MX360019B (es) 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
EA201171284A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Новая технология изготовления напроксена
KR101580656B1 (ko) 2009-04-24 2015-12-30 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
US8871245B2 (en) 2012-02-28 2014-10-28 Nichiban Co., Ltd. Transdermal patch
HRP20250965T1 (hr) 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
US20140287039A1 (en) 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
WO2017136617A1 (en) * 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US11364226B2 (en) * 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
KR20240068762A (ko) * 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
EP4525868A1 (en) * 2022-04-20 2025-03-26 CinDome Pharma, Inc. Deuterated domperidone for treating gastroparesis

Similar Documents

Publication Publication Date Title
JP2020534246A5 (https=)
JP2019514354A5 (https=)
JP2019502892A5 (https=)
JP2019504068A5 (https=)
JP2006526031A5 (https=)
EA200600049A1 (ru) Способы получения 3 - бензазепинов
JP2013540292A5 (https=)
JP2022521336A5 (https=)
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
JP2018525453A5 (https=)
JP2020512939A5 (https=)
RU2017102513A (ru) Соль гетероциклического соединения, замещенного галогеном
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
RU2427573C2 (ru) Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)
JP2020505322A5 (https=)
TNSN07227A1 (fr) Derives de chromane utiles comme antagonistes de la pompe a acide
JP2023521031A5 (https=)
JP2006510659A5 (https=)
JP2022536408A5 (https=)
JP2023503428A5 (https=)
JP2021534984A5 (https=)
CN109476584A (zh) N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途
JP2024523149A5 (https=)
JP2017532647A5 (https=)
MAGHSOUDI et al. Zizyphus jujuba seed essential oil inhibits lipopolysaccharide-stimulated THP-1 cells invasion and migration through suppression of matrix metalloproteinase-9 expression